Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03668340 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03668340 · ClinicalTrials.gov record · last posted 2026-08-25

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Name: AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma — clinical trial record (NCT03668340)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorDana-Farber Cancer Institute

Started2018-10-22

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This research study is studying an investigational drug as a possible treatment for uterine cancer. The drug involved in this study is: -AZD1775

Protocol amendment history 2 changes detected by DataLookout

2026-08-26

Primary completion pushed: 2026-07-01 → 2026-09-01

2026-08-26

Completion pushed: 2027-07-01 → 2027-09-01

Trial Details

NCT Number	NCT03668340
Lead Sponsor	Dana-Farber Cancer Institute Collaborators: AstraZeneca
Conditions	Uterine Cancer
Enrollment	49 participants
Start Date	2018-10-22
Primary Completion	2026-09-01 (estimated)
Study Completion	2027-09-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-25